Preview

Онкоурология

Расширенный поиск

Органосохраняющее лечение при инвазивном раке мочевого пузыря

https://doi.org/10.17650/1726-9776-2005-1-2-27-31

Полный текст:

Об авторе

Д. Х. Микич
Центр оперативной урологии Бремена, Академический госпиталь «Links der Weser»
Германия
Бремен


Список литературы

1. Shipley W.U., Kaufman D.S., Heney N.M. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy // J. Urol. — 1999;162:445—451.

2. Sternberg C.N., Arena M.G., Calabresi F. Neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder // Cancer. — 1993;72:1975—1982.

3. Rivera I., Wajsman Z. Bladder-sparing treatment of invasive bladder cancer // Cancer Contr. — 2000; 7:340—346.

4. Kim H.L., Steinberg G.D. The current status of bladder preservation in the treatment of muscle invasive bladder cancer // J. Urol. — 2000; 164: 627—632.

5. Solsona E., Iborra I., Ricos J.V. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study // J. Urol. — 1998;159:95—99.

6. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors // J. Urol. — 1999;162:74—76.

7. Holzbeierlein J.M., Lopez-Corona E., Bochner B.H. et al. Partial cystectomy: a con-temporaray review of the Memorial-Sloan-Kettering Cancer Center experience and recommendations for patient selection // J. Urol. — 2004; 172: 878—881.

8. Montie J.E. Against bladder sparing: surgery // J. Urol. — 1999; 162:452—457.

9. Kuczyk M., Turkeri L., Hammerer P., Ravery V. Is there a role for bladder preserving strategies in the treatment of muscle-unvasive bladder cancer? // Eur. Urol. — 2003; 44: 57—64.

10. Holmang S., Hedelin H., Borghede G. Long-term follow up of a bladder carcinoma cohort: questionable value of radical radiotherapy // J. Urol. — 1997;157:1642—1646.

11. Eapen L., Stewart D., Crook J. Intraarterial cisplatin (IAC) and concurrent pelvic radiation (PR) in the management of transitional bladder cancer: an organ preservation strategy. Proc. Annu Meet. Am. Soc. Clin. Oncol. — 1995;14:A625.

12. Wijnmaalen A., Helle P.A., Koper P.C. et al. Muscle invasive bladder cancer treated by transurethral resection followed by external beam radiation and interstitial iridium-192 // Int. J. Radiat. Oncol. Biol. Phys. — 1997;39:1043—1052.

13. Shipley W.U., Winter K.A., Kaufman D.S. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 // J. Clin. Oncol. — 1998;16:3576—3583.

14. Gschwend J.E., Vieweg J., Fair W.R. Disease specific survival after radical cystectomy // J. Urol. — 1997;157:1662A.

15. Cheng L., Neumann R.M., Scherer B.G. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion // Cancer. — 1999;85:2638—2647.

16. Hart S., Skinner E.C., Meyerowitz B.E. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit,cutaneous or urethral kock pouch // J. Urol. — 1999; 162:77—81.


Для цитирования:


Микич Д.Х. Органосохраняющее лечение при инвазивном раке мочевого пузыря. Онкоурология. 2005;1(2):27-31. https://doi.org/10.17650/1726-9776-2005-1-2-27-31

For citation:


Mickisch G.H. Partial Cystectomy for Invasive Bladder Cancer. Cancer Urology. 2005;1(2):27-31. (In Russ.) https://doi.org/10.17650/1726-9776-2005-1-2-27-31

Просмотров: 60


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X